Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome
Authors:
- Pantelis PapoutsakisPPPantelis Papoutsakis
- Ioannis KallikazarosIKIoannis Kallikazaros
- Christos StefanadisCSChristos Stefanadis
- 1 April 1990
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 27 (1) , 63-70
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardiaThe American Journal of Cardiology, 1985
- Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardiaJACC, 1985
- Effect of propafenone in the wolff-parkinson-white syndrome: Electrophysiologic findings and long-term follow-upThe American Journal of Cardiology, 1984
- Clinical pharmacology of propafenone: Pharmacokinetics, metabolism and concentration-response relationsThe American Journal of Cardiology, 1984
- Clinical pharmacology of propafenone.Circulation, 1983
- Electrophysiological and Antiarrhythmic Properties of Propafenon in Isolated Cardiac PreparationsJournal of Cardiovascular Pharmacology, 1981
- Electrophysiological effects of propafenone studied with programmed electrical stimulation of the heart in patients with recurrent paroxysmal supraventricular tachycardiaEuropean Heart Journal, 1981
- Effects of propafenon on the accessory pathway (AP) in patients with WPW syndromeThe American Journal of Cardiology, 1979
- Wirksamkeit und Risiken von Propafenon bei der Akutbehandlung von HerzrhythmusstörungenDMW - Deutsche Medizinische Wochenschrift, 1978
- Mitral valve prolapseThe American Journal of Medicine, 1977